10% Off
Dualvir90 mg+400
Aristopharma Ltd.
৳6300.00
Add to cart
Generic medicine
Ledipasvir + Sofosbuvir: Brands, Price & Uses in Bangladesh
Ledipasvir + Sofosbuvir is a fixed-dose combination of two direct-acting antiviral (DAA) agents indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and select…
About Ledipasvir + Sofosbuvir
Indications of Ledipasvir + Sofosbuvir
Ledipasvir + Sofosbuvir is a fixed-dose combination of two direct-acting antiviral (DAA) agents indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and select pediatric patients. Evidence and approval status vary by clinical scenario:
Established / Approved Uses
- Chronic HCV genotype 1, 4, 5, or 6 infection in adults and pediatric patients ≥3 years of age, without cirrhosis or with compensated (Child-Pugh A) cirrhosis, used alone.
- Chronic HCV genotype 1 infection with decompensated cirrhosis, used in combination with ribavirin.
- Chronic HCV genotype 1 or 4 infection in liver transplant recipients without cirrhosis or with compensated cirrhosis, used in combination with ribavirin.
- HCV/HIV-1 co-infected patients with chronic HCV genotype 1, 4, 5, or 6 infection, using the same regimen as HCV mono-infected patients.
Uses Requiring Combination Therapy
In patients with decompensated cirrhosis or in certain liver transplant recipients, Ledipasvir + Sofosbuvir is not used alone; it must be combined with ribavirin as directed by a hepatologist/gastroenterologist experienced in HCV management.
Not Recommended / Not Indicated
Ledipasvir + Sofosbuvir is not recommended for HCV genotypes for which adequate efficacy data are lacking (e.g., genotype 2 or 3 monoinfection), and it does not treat other viral hepatitis infections (hepatitis A or B) or non-HCV liver disease.
Dosage & Administration of Ledipasvir + Sofosbuvir
Ledipasvir + Sofosbuvir is administered orally, once daily, with or without food. The recommended treatment duration depends on HCV genotype, prior treatment history, and presence/severity of cirrhosis.
| Patient Population | Treatment Duration |
|---|---|
| Treatment-naïve, no cirrhosis | 8–12 weeks (8 weeks may be considered in select genotype 1 patients with baseline HCV RNA <6 million IU/mL) |
| Treatment-naïve, with compensated cirrhosis | 12 weeks |
| Treatment-experienced, no cirrhosis | 12 weeks |
| Treatment-experienced, with compensated cirrhosis | 24 weeks (or 12 weeks with ribavirin, per specialist judgment) |
| Decompensated cirrhosis (with ribavirin) | 12 weeks |
| Liver transplant recipients (with ribavirin) | 12 weeks (no/compensated cirrhosis) or 24 weeks (decompensated cirrhosis) |
Missed doses: if a dose is missed and remembered within 18 hours of the usual time, the patient should take it as soon as possible and then resume the normal schedule; if more than 18 hours have passed, the missed dose should be skipped and the next dose taken at the regular time. A double dose should not be taken. The full course must be completed exactly as prescribed (see Precautions).
Side Effects of Ledipasvir + Sofosbuvir
Ledipasvir + Sofosbuvir is generally well tolerated. The most commonly reported adverse effects (used alone, without ribavirin) include:
- Fatigue
- Headache
Other reported adverse effects include nausea, diarrhea, insomnia, and asthenia. When Ledipasvir + Sofosbuvir is given together with ribavirin, additional adverse effects associated with ribavirin — most notably anemia — are more frequent. Serious adverse effects are uncommon but include hepatitis B reactivation and serious bradyarrhythmias with concomitant amiodarone (see Precautions and Interactions). Patients should report any unusual or severe symptoms to their physician promptly.
Contraindications of Ledipasvir + Sofosbuvir
Ledipasvir + Sofosbuvir is contraindicated in:
- Patients with known hypersensitivity to ledipasvir, sofosbuvir, or any excipient of the formulation.
- Coadministration with rifampin (a potent P-glycoprotein/CYP inducer), which significantly reduces ledipasvir and sofosbuvir plasma concentrations and may lead to loss of virologic response.
- When Ledipasvir + Sofosbuvir is used together with ribavirin (in decompensated cirrhosis or transplant regimens), the contraindications applicable to ribavirin also apply to that combination — this includes pregnancy (in the patient or the partner of a male patient) and hemoglobinopathies such as thalassemia major or sickle-cell anemia.
Frequently Asked Questions about Ledipasvir + Sofosbuvir
What is Ledipasvir + Sofosbuvir used for?
Ledipasvir + Sofosbuvir is used to treat chronic hepatitis C virus (HCV) infection, most commonly genotypes 1, 4, 5, or 6, in adults and children 3 years of age and older. It is taken as a once-daily tablet, usually for 8 to 24 weeks depending on the individual case.
How long does treatment with Ledipasvir + Sofosbuvir last?
The duration of Ledipasvir + Sofosbuvir treatment is individualized by the physician based on HCV genotype, whether the patient has been treated before, and whether cirrhosis is present. Most courses last 8, 12, or 24 weeks. It is essential to complete the entire prescribed course even if you feel well, to achieve cure and avoid resistance.
Can Ledipasvir + Sofosbuvir be taken during pregnancy?
Ledipasvir + Sofosbuvir should be used in pregnancy only if clearly needed and if the potential benefit outweighs the potential risk to the baby, and only under a physician's close supervision, because data in pregnant women are limited. If it is prescribed together with ribavirin, pregnancy must be avoided completely, since ribavirin can cause serious birth defects; effective contraception is required in that situation. Always consult your physician before use in pregnancy.
What should I avoid while taking Ledipasvir + Sofosbuvir?
Avoid taking Ledipasvir + Sofosbuvir together with rifampin or other strong enzyme-inducing medicines, as these can make Ledipasvir + Sofosbuvir ineffective. Coadministration with amiodarone should generally be avoided due to a risk of serious slow heart rhythms. Certain acid-reducing medicines (antacids, H2-blockers, proton pump inhibitors) need to be timed carefully around your dose. Always tell your doctor about every medicine, supplement, and herbal product you are taking.
What are the common side effects of Ledipasvir + Sofosbuvir?
The most common side effects of Ledipasvir + Sofosbuvir are fatigue and headache. Other effects can include nausea, diarrhea, and difficulty sleeping. If taken with ribavirin, anemia is more common. Most side effects are mild; contact your physician if you experience anything severe or unusual.
Is Ledipasvir + Sofosbuvir safe for children?
Ledipasvir + Sofosbuvir is approved for children 3 years of age and older with appropriate HCV genotypes, using a weight-based dose. It has not been studied in children under 3 years old, so it should not be used in that age group. A pediatric specialist should guide dosing and monitoring in children.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.